AI, biology poised to scratch each other’s back

Beyond DNA strands, biological data comes in a host of disparate forms, from gene expressions to electrical signals to advanced imaging. In fact the aggregated datasets are so complex, applying algorithmic analysis for medical uses may help expand AI as it unlocks biology.

The dynamic is described in an Axios item posted April 8.

“[T]he nuanced, complex biological data captured by imaging and [genome] sequencing could help to create powerful algorithms that capture cause and effect in a system,” explains reporter Alison Snyder. “That would represent a leap forward for AI, which remains best at identifying correlations while leaving the question of cause to human scientists.”

The bottom line, Snyder suggests, quoting Harvard/MIT physician/geneticist/data scientist Anthony Philippakis, is that blending AI with biology “may not just be another tool for understanding medicine. Biology could be ‘a driver for the next generation of advances in machine learning.’”

Read the whole thing.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.